EASD 2026: Orforglipron shows an efficacy edge over oral semaglutide in T2D
Orforglipron shows modestly greater weight and HbA1c reductions than oral semaglutide, supporting its potential in type 2 diabetes.
Read the full article on the original site.
Read Full Article